EULAR 2019 Report – Day 2

Save

It was a full and lively 2nd day in Madrid with sessions dedicated to Lupus, RA, Sjogren’s, imaging, rare diseases, psoriatic arthritis and spondyloarthritis. Here are a few of the highlights from day 2 EULAR in Madrid 

EULAR 2019 - Day 1 Report

Save

Here are a few of the highlights from day 1 EULAR in Madrid. 

Industry Press Releases from EULAR19

Save

Many of the great presentations from EULAR 2019 feature industry sponsored clinical trials.  Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.

Preview of EULAR 2019 Abstracts

Save

EULAR 2019 begins today in Madrid and features over 2000 presentations.  After an initial review of titles and abstracts, I’ve compiled a hit list of presentations of interest to me and hopefully other practicing rheumatologists.  

When Your Patient Asks Why?

Save

This is probably the most difficult question that a physician is confronted with. A patient is stricken with a new disease or problem and before it even sinks in or is fully comprehended, the patient wants to know “why” or “how” long before they want to know what are we can do about it.

Management of Hemophagocytic Lymphohistiocytosis (HLH) in Adults

Save

Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome induced by activated macrophages and cytotoxic T cells.  HLH manifests recurrent fever, cytopenia, liver dysfunction, and a sepsis-like syndrome that may complicated by multiple organ failure.

Updated 2018 EULAR Recommendations for the Diagnosis of Gout

Save

The first EULAR recommendations for the diagnosis of gout were published in 2006. A task force was formed and following a systematic review, they voted unanimously for changes in all items of the 2006 recommendations.

RheumNow Podcast – Drug Ad Transparency (6.7.19)

Save

Dr. Jack Cush reviews the news and journal articles of note from this past week on RheumNow.com.

More Trouble for Mallinckrodt’s Acthar Gel

Save

Reuters has reported that Mallinckrodt Plc has tentatively agreed to pay $15.4 million to resolve a US Justice Department investigation into company promotional practices for Acthar gel.

Low Remission/LDA Rates with TNF inhibitors in Rheumatoid Arthritis

Save